Cargando…

Targeting MDSCs enhance therapeutic vaccination responses against lung cancer

Myeloid-derived suppressor cells (MDSCs) are important regulators of immune responses. These cells suppress the cytotoxic activities of natural killer (NK)-cell and T-cell effectors and promote tumor growth. We demonstrated that depleting MDSCs improve therapeutic responses to vaccination in a murin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srivastava, Minu K., Dubinett, Steven, Sharma, Sherven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525634/ https://www.ncbi.nlm.nih.gov/pubmed/23264925 http://dx.doi.org/10.4161/onci.21970

Ejemplares similares

Catechins and antitumor immunity: Not MDSC’s cup of tea
por: Santilli, Giorgia, et al.
Publicado: (2013)

Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth
por: Fujimura, Taku, et al.
Publicado: (2012)

NKT cell adjuvants in therapeutic vaccines against hematological cancers
por: Mattarollo, Stephen R., et al.
Publicado: (2013)

Lung specific X protein as a novel therapeutic target for lung cancer
por: Zheng, Xiaohu, et al.
Publicado: (2015)

TG4010: A therapeutic vaccine against MUC1 expressing tumors
por: Limacher, Jean-Marc, et al.
Publicado: (2012)

Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer
por: Srivastava, Minu K, et al.
Publicado: (2012)

Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines
por: García-Vallejo, Juan J., et al.
Publicado: (2013)

Tumor-targeting vaccination instructs graft-vs.-tumor immune responses
por: Manzo, Teresa, et al.
Publicado: (2013)

Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?
por: Cioffi, Michele, et al.
Publicado: (2012)

Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines
por: Shirwan, Haval, et al.
Publicado: (2013)

The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancer
por: Sawant, Anandi, et al.
Publicado: (2014)

PARP1 inhibition elicits immune responses against non-small cell lung cancer
por: Juncheng, Pan, et al.
Publicado: (2022)

Antibody-based therapeutics against components of the IGF system
por: Feng, Yang, et al.
Publicado: (2012)

The adenosinergic system in cancer: Key therapeutic target
por: Sorrentino, Rosalinda, et al.
Publicado: (2013)

Prostate cancer: Important steps and considerations in the design of therapeutic vaccines
por: McArdle, Stephanie EB, et al.
Publicado: (2014)

Chemokine-enhanced DNA vaccination in cancer immunotherapy
por: Igoucheva, Olga, et al.
Publicado: (2013)

YES, a novel therapeutic target in hepatocellular carcinoma
por: Lapouge, Marjorie, et al.
Publicado: (2022)

Targeting the tumor mutanome for personalized vaccination therapy
por: Kreiter, Sebastian, et al.
Publicado: (2012)

Hedgehog-targeted therapeutics uncouple the vicious cycle of bone metastasis
por: Hurchla, Michelle A., et al.
Publicado: (2012)

CD4 responses against IDO
por: Andersen, Mads Hald
Publicado: (2012)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Mammaglobin-A is a target for breast cancer vaccination
por: Kim, Samuel W., et al.
Publicado: (2016)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Targeting cancer stem cells via dendritic-cell vaccination
por: Teitz-Tennenbaum, Seagal, et al.
Publicado: (2012)

The peripheral immune response and lung cancer prognosis
por: Showe, Michael K., et al.
Publicado: (2012)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Predicting the efficacy of cancer vaccines by evaluating T-cell responses
por: van Duikeren, Suzanne, et al.
Publicado: (2013)

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
por: Calabrò, Luana, et al.
Publicado: (2014)

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer
por: Erstad, Derek J., et al.
Publicado: (2017)

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
por: Demaria, Sandra, et al.
Publicado: (2013)

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
por: Peng, Weiyi, et al.
Publicado: (2013)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants
por: Weiskopf, Kipp, et al.
Publicado: (2013)

An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
por: Palena, Claudia, et al.
Publicado: (2014)

Membrane-bound KIT ligand-targeting DNA vaccination inhibits mammary tumor growth
por: Dentelli, Patrizia, et al.
Publicado: (2014)

Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
por: Hunn, Martin K., et al.
Publicado: (2013)

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
por: Madan, Ravi A, et al.
Publicado: (2014)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target
por: Noman, Muhammad Zaeem, et al.
Publicado: (2018)

Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
por: Rathore, Richa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_makeii2f3o373rs2lv6k9bog2p